OVERVIEW
First Wave BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its three proprietary technologies – capeserod, a selective 5-HT4 receptor partial agonist for GI indications; the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-inflammatory properties.
